• LAST PRICE
    9.5400
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    7.5000/ 20
  • Ask / Lots
    14.4600/ 3
  • Open / Previous Close
    0.0000 / 9.5400
  • Day Range
    ---
  • 52 Week Range
    Low 4.8900
    High 16.6500
  • Volume
    1
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 9.8
TimeVolumeORIC
09:32 ET50379.78
09:36 ET16119.79
09:41 ET7079.89
09:43 ET1009.91
09:45 ET5009.935
09:50 ET1009.92
09:56 ET17399.91
10:01 ET1009.94
10:03 ET4149.9
10:06 ET4299.83
10:08 ET1009.77
10:12 ET1009.77
10:14 ET2009.745
10:15 ET26399.745
10:17 ET5009.775
10:21 ET2009.77
10:26 ET3009.8
10:33 ET6009.8
10:35 ET1009.77
10:37 ET8099.875
10:42 ET2529.84
10:44 ET1009.845
10:48 ET13009.8
10:51 ET2009.815
10:53 ET1009.79
10:57 ET1009.84
11:00 ET11109.82
11:04 ET6159.8375
11:06 ET10369.84
11:08 ET1009.83
11:09 ET2549.82
11:11 ET1009.81
11:18 ET1009.81
11:20 ET11019.78
11:22 ET14069.78
11:24 ET2949.74
11:26 ET2009.7395
11:27 ET2009.76
11:33 ET1009.78
11:40 ET3009.7725
11:42 ET2459.78
11:44 ET4009.79
11:51 ET3009.79
11:56 ET1009.805
12:00 ET6449.7935
12:02 ET1009.82
12:07 ET13009.76
12:09 ET3009.77
12:14 ET8859.75
12:18 ET1019.75
12:20 ET4509.75
12:21 ET4509.751
12:25 ET3009.7
12:27 ET1009.69
12:32 ET7019.65
12:34 ET8009.65
12:36 ET3009.65
12:38 ET3009.63
12:39 ET1009.61
12:41 ET9159.64
12:45 ET1009.61
12:48 ET1009.59
12:50 ET61929.6
12:52 ET43839.605
12:56 ET2019.61
12:59 ET6009.61
01:01 ET8119.6
01:06 ET4009.62
01:10 ET3189.66
01:12 ET2009.66
01:17 ET3439.695
01:19 ET6689.68
01:24 ET2009.7
01:28 ET2009.71
01:30 ET17359.69
01:32 ET1119.67
01:33 ET1269.65
01:37 ET1099.6559
01:42 ET5229.68
01:46 ET1009.69
01:48 ET9339.72
01:50 ET2009.72
01:51 ET1009.72
01:53 ET8219.71
01:55 ET2009.7
01:57 ET7059.711
02:00 ET1009.74
02:04 ET9009.72
02:06 ET1009.735
02:08 ET1009.73
02:09 ET2009.72
02:11 ET3009.705
02:18 ET3009.69
02:20 ET2009.68
02:22 ET6009.69
02:24 ET4009.65
02:27 ET14679.59
02:29 ET24209.57
02:33 ET1339.52
02:36 ET77399.53
02:40 ET12009.5
02:42 ET8239.5
02:44 ET3079.5
02:45 ET1009.5
02:49 ET6009.46
02:51 ET16959.4659
02:54 ET3319.46
02:56 ET18719.47
02:58 ET23469.43
03:00 ET3009.45
03:02 ET7009.42
03:03 ET11889.42
03:05 ET51689.4
03:07 ET6409.38
03:09 ET2009.35
03:12 ET15259.38
03:14 ET21369.42
03:16 ET13329.44
03:18 ET9049.43
03:20 ET6009.42
03:21 ET7599.43
03:23 ET85829.38
03:25 ET3539.39
03:27 ET15179.36
03:30 ET23969.37
03:32 ET4009.36
03:34 ET5699.36
03:36 ET38609.39
03:38 ET18869.38
03:39 ET16279.39
03:41 ET8509.4
03:43 ET42349.41
03:45 ET26149.42
03:48 ET44379.39
03:50 ET36149.405
03:52 ET62009.505
03:54 ET80589.51
03:56 ET173579.47
03:57 ET140709.55
03:59 ET136169.54
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesORIC
Oric Pharmaceuticals Inc
642.8M
-4.8x
---
United StatesALXO
ALX Oncology Holdings Inc
646.5M
-3.4x
---
United StatesPRME
Prime Medicine Inc
652.5M
-2.5x
---
United StatesCOGT
Cogent Biosciences Inc
621.5M
-2.7x
---
United StatesLBPH
Longboard Pharmaceuticals Inc
613.3M
-7.6x
---
United StatesNKTX
Nkarta Inc
612.8M
-3.6x
---
As of 2024-04-16

Company Information

ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.

Contact Information

Headquarters
240 E. Grand Ave, 2nd FloorSOUTH SAN FRANCISCO, CA, United States 94080
Phone
650-388-5600
Fax
302-655-5049

Executives

Independent Chairman of the Board
Richard Heyman
President, Chief Executive Officer, Director
Jacob Chacko
Chief Financial Officer
Dominic Piscitelli
Chief Medical Officer
Pratik Multani
Independent Director
Mardi Dier

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$642.8M
Revenue (TTM)
$0.00
Shares Outstanding
67.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.15
EPS
$-1.97
Book Value
$4.08
P/E Ratio
-4.8x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.